Eli Lilly (NYSE: LLY) received an emergency use authorization from the Food and Drug Administration for its COVID-19 treatment, bamlanivimab, on Monday afternoon.
The drug is a therapeutic antibody designed to bind to the novel coronavirus that causes COVID-19.
The authorization covers patients aged 12 or older who have mild to moderate COVID-19, are at high risk for progressing to severe COVID-19, and might require hospitalization.
